

1 **Pattern-mixture model in network meta-analysis of binary missing outcome**
2 **data: one-stage or two-stage approach?**

3

4 Loukia M. Spinelis^{1*} Spinelis.Loukia@mh-hannover.de

5 Katerina Papadimitropoulou² a.papadimitropoulou@lumc.nl

6 Chrysostomos Kalyvas³ chrysostomos.kalyvas@merck.com

7

8 ¹Midwifery Research and Education Unit, Hannover Medical School, Hannover,
9 Germany

10 ²Department of Clinical Epidemiology, Leiden University Medical Center,
11 Leiden, The Netherlands

12 ³Department of Biostatistics and Research Decision Sciences, MSD Europe Inc,
13 Brussels, Belgium

14

15 *Corresponding author: Loukia M. Spinelis, Midwifery Research and Education
16 Unit (OE 6410), Hannover Medical School, Carl-Neuberg-Straße 1, 30625,
17 Hannover, Germany.

18 E-mail: Spinelis.Loukia@mh-hannover.de

19 Telephone: +49 (0) 511 532 – 83593

20 Fax: +49 (0) 511 532 – 6191

21

22

23

1 **Abstract**

2 **Background:** Trials with binary outcomes can be synthesised using within-trial exact
3 likelihood or approximate normal likelihood in one-stage or two-stage approaches,
4 respectively. The advantages of the one-stage over the two-stage approach have been
5 documented extensively in the literature. Little is known how these approaches behave in the
6 presence of missing outcome data (MOD) which are ubiquitous in trials. In this work, we
7 compare the one-stage versus two-stage approach via a pattern-mixture model in the network
8 meta-analysis Bayesian framework to handle MOD appropriately.

9 **Methods:** We used 29 published networks to empirically compare the two approaches with
10 respect to the relative treatment effects of several competing interventions and the between-
11 trial variance (τ^2). We categorised the networks according to the extent and balance of MOD
12 in the included trials. To complement the empirical study, we conducted a simulation study to
13 compare the competing approaches regarding bias and width of the 95% credible interval of
14 the (summary) log odds ratios (OR) and τ^2 in the presence of moderate and large MOD.

15 **Results:** The empirical study did not reveal any systematic bias between the compared
16 approaches regarding the log OR, but showed systematically larger uncertainty around the log
17 OR under the one-stage approach for networks with at least one small trial or low event risk
18 and moderate MOD. For these networks, the simulation study revealed that the bias in log OR
19 for comparisons with the reference intervention in the network was relatively higher in the
20 two-stage approach. Contrariwise, the bias in log OR for the remaining comparisons was
21 relatively higher in the one-stage approach. Overall, bias increased for large MOD.
22 Furthermore, in these networks, the empirical results revealed slightly higher τ^2 estimates
23 under the one-stage approach irrespective of the extent of MOD. The one-stage approach also
24 led to less precise log OR and τ^2 when compared with the two-stage approach for large
25 MOD.

26 **Conclusions:** Due to considerable bias in the log ORs overall, especially for large MOD,
27 none of the competing approaches was superior. Until a more competent model is developed,
28 the researchers may prefer the one-stage approach to handle MOD, while acknowledging its
29 limitations.

30 **Keywords:** network meta-analysis; missing outcome data; pattern-mixture model; Bayesian
31 methods; one-stage approach; two-stage approach; simulation study.

1 **Background**

2 To address aggregate binary missing participant outcome data (MOD) in pairwise and
3 network meta-analysis, the researchers usually resort to exclusion or imputation – both
4 popular approaches for their simplicity (1–3), yet notorious for the implausibility of their
5 assumptions. A statistically and conceptually appropriate approach is to model MOD
6 simultaneously with the observed outcomes. This approach naturally accounts for the
7 uncertainty due to MOD, and it may also safeguard against biased results by adjusting the
8 within-trial results (treatment effect and standard error) for MOD (4). Since modelling of
9 MOD does not require any data manipulation prior to analysis, it overrides both exclusion and
10 imputation.

11 The pattern-mixture model is the most commonly described model in the methodological
12 literature for pairwise and network meta-analysis to address binary MOD (4–7). It consists of
13 two parts: a model for the outcome conditional on being missing or observed and a model for
14 the probability of MOD (8). The pattern-mixture model incorporates an informative
15 missingness parameter, which describes our belief about the missingness mechanism. In the
16 case of binary data, this informative missingness parameter is known as the informative
17 missingness odds ratio parameter (IMOR) and quantifies departures from the missing at
18 random (MAR) assumption (4,6,7,9). The IMOR parameter is defined as the ratio between the
19 odds of an event among MOD and the odds of an event among participants completing the
20 trial (referred as completers). The IMOR parameter is naturally unknown and we can only
21 make clinically plausible assumptions for its value. Under the Bayesian framework, IMOR is
22 commonly assigned a normal prior distribution in the logarithmic scale with mean and
23 variance indicating our on average prior belief and uncertainty about the missingness
24 mechanism, respectively (4,6).

25 The pattern-mixture model can be applied under both the exact and approximate likelihood
26 methods. The former (more frequently – but not exclusively – applied using Bayesian
27 methods) commonly assumes within-trial binomial distribution, and thus, uses logistic
28 regression to estimate the within-trial log ORs and their standard errors in a single step
29 (hereafter the one-stage pattern-mixture (PM) approach). Under this approach, the log IMOR
30 is assigned a normal prior distribution with various options regarding its structure (such as
31 identical, exchangeable, or independent across trials, trial-specific, intervention-specific)
32 rendering this approach very appealing and flexible (4,6). In a two-stage pattern-mixture
33 model (hereafter the two-stage PM approach), initially, log ORs and standard errors are

1 calculated in each trial after adjusting for a scenario about the missingness process (e.g. MAR
2 as a starting point) – expressed via the mean and variance of log IMORs. Then, the adjusted
3 log ORs are pooled using inverse-variance weighting (7,10).

4 Albeit being more straightforward to apply, the two-stage PM approach has several
5 shortcomings – most of them inherent to the within-trial normal approximation. By fixing the
6 within-trial results to the assumed mean and variance of log IMOR, the two-stage PM
7 approach does not allow the observed data to contribute to the estimation of log IMOR to gain
8 further insights on the missingness process in the collected trials (4). Furthermore, note that
9 the adjusted within-trial treatment effects and variances – the latter assumed known, although
10 estimated, under the normal distribution – comprise the dataset for the second stage of the
11 two-stage PM approach. In the presence of zero cells, continuity correction is thus required –
12 a suboptimal approach that has been criticised for leading to biased results (11,12). In a
13 typical systematic review where large and many studies are not prevalent, it is hard to justify
14 the within-trial normal approximation (13,14). Consequently, the application of the two-stage
15 PM approach may implicate the accuracy of summary results (especially, when the included
16 trials are small, or the outcome is sparse (15)), and hence, compromise the conclusions
17 delivered to the end-users of systematic reviews.

18 The advantages of the exact likelihood (one-stage approach) over the approximate normal
19 likelihood (two-stage approach) for the synthesis of trials are well-documented in the
20 literature for pairwise meta-analysis (16–18) and recently for network meta-analysis (NMA)
21 (19). However, little is known whether and how much the presence of MOD can challenge the
22 behaviour of these two approaches. In this work, we investigate the implications of one-stage
23 and two-stage PM approaches to handle aggregate binary MOD on the relative treatment
24 effects and the between-trial variance in NMA. In Section “Methods”, we introduce the one-
25 stage and two-stage PM approaches for binary MOD in Bayesian random-effects NMA, and
26 we briefly describe the empirical study. The results of the empirical study appear in the
27 homonymous section followed by the Section “Simulation study” where we describe the set-
28 up and the various scenarios of our simulation study. In Section “Results of the simulation
29 study”, we present the results of the simulation study. Discussion of the findings from the
30 empirical and simulations studies can be found in Section “Discussion”, and brief conclusions
31 and recommendations are followed-up in Section “Conclusions.”

32 **Methods**

1 Consider a network of N trials that compare different sets of T interventions regarding a
 2 binary outcome. In arm $k = 1, 2, \dots, a_i$ of trial i , we report the number of observed events, r_{ik}^o ,
 3 and the number of missing participants, m_{ik} , out of the total randomised, n_{ik} .

4 ***One-stage pattern-mixture model***

5 By convention, r_{ik}^o and m_{ik} are assumed to follow the corresponding binomial distributions:

$$6 \quad r_{ik}^o \sim \text{Bin}(p_{ik}^o, n_{ik} - m_{ik}) \text{ and } m_{ik} \sim \text{Bin}(q_{ik}, n_{ik})$$

7 where p_{ik}^o is the probability of an event conditional on completers, $n_{ik} - m_{ik}$, and q_{ik} is the
 8 probability of MOD in arm k of trial i (4,6).

9 Under the pattern-mixture model, the randomised participants are distinguished to those
 10 completing and those dropping out of the trial early. Within each subgroup, the participants
 11 are further distinguished to those experiencing and those not experiencing the outcome. Then,
 12 the underlying probability of an event, p_{ik} , can be written as a function of these subgroups
 13 using conditional probabilities (4):

$$p_{ik} = p_{ik}^o(1 - q_{ik}) + p_{ik}^m q_{ik} \quad (1)$$

14 with p_{ik}^m being the probability of an event conditional on those dropping out of arm k in trial
 15 i . Then, the IMOR parameter is defined as follows (7):

$$16 \quad \delta_{ik} = \frac{p_{ik}^m / (1 - p_{ik}^m)}{p_{ik}^o / (1 - p_{ik}^o)}$$

17 with

$$18 \quad \log(\delta_{ik}) = \varphi_{ik} \sim N(\omega_{ik}, \sigma_{ik}^2)$$

19 In the present work, we considered independent φ_{ik} to agree with the structure of φ_{ik} in the
 20 two-stage PM approach (Section “two-stage pattern-mixture model”):

$$21 \quad \varphi_{ik} \sim N(0, 1)$$

22 where we assume on average MAR in each arm of every trial.

23 ***Random-effects network meta-analysis model***

24 Then, the logit function with random-effects is applied:

$$1 \quad \text{logit}(p_{ik}) = u_i + \theta_{ik}$$

$$2 \quad \theta_{ik} \sim N(\mu_{t_{ik}t_{i1}}, \tau^2)$$

3 with $u_i = \text{logit}(p_{i1})$ being the log odds of baseline arm and θ_{ik} being the log OR of an event
 4 between arm k ($k \neq 1$) and baseline arm in trial i . Index t_{ik} indicates the intervention studied
 5 in arm k of trial i , that is, $t_{ik} \in \{A, B, \dots, T\}$. Typically, τ^2 is assumed common for all
 6 observed comparisons; this corresponds to a correlation equal to 0.5 between any two θ_{ik} s
 7 (with $k \neq 1$) in a multi-arm trial (20).

8 Under the consistency assumption (i.e. an agreement between direct and more than one
 9 indirect sources of evidence for a comparison (21)), we can obtain all possible pairwise
 10 comparisons as linear combinations of the summary log ORs of the basic parameters (i.e.
 11 comparisons with the reference intervention in the network (22)):

$$12 \quad \mu_{jl} = \mu_{jA} - \mu_{lA}$$

13 with $j \neq l \in \{B, C, \dots, T\}$ and A as the reference intervention in the network. Using the basic
 14 parameters, we can also obtain several measures of hierarchy to order the interventions from
 15 the best to worst (23). However, intervention hierarchy is out of the scope of the present
 16 study.

17 ***Two-stage pattern-mixture model***

18 In the first stage, we adjust the within-trial log ORs using the pattern-mixture model (equation
 19 (1)). Assuming that log IMORs are on average MAR in each arm of every trial (i.e. $\omega_{ik} = 0$),
 20 $p_{i,k}$ corresponds to $r_{ik}^o / (n_{ik} - m_{ik})$. Then, the log OR of an event between arm k ($k \neq 1$) and
 21 baseline arm in trial i is estimated as:

$$22 \quad y_{ik} = \begin{cases} \text{logit}(r_{ik}^o / (n_{ik} - m_{ik})) - \text{logit}(r_{i1}^o / (n_{i1} - m_{i1})) & , \text{ no zero cells} \\ \text{logit}((r_{ik}^o + 0.5) / (n_{ik} - m_{ik} + 1)) - \text{logit}((r_{i1}^o + 0.5) / (n_{i1} - m_{i1} + 1)) & , \text{ zero cells} \end{cases}$$

23 Under the pattern-mixture model, the within-trial variance of log OR, v_{ik} , is partitioned to
 24 variance due to sampling error and to variance arising from φ_{ik} . In the present work, to
 25 approximate the variance due to sampling error, we applied Taylor series (equation (13) in
 26 (7)), and for the variance due to φ_{ik} we used the equation (16) in (7) assuming zero
 27 correlation between φ_{ik} s of the compared arms in each trial and σ_{ik}^2 equal to 1. By
 28 convention, v_{ik} is treated as known based on the central limit theorem that trials are
 29 sufficiently large so that y_{ik} approximates the normal distribution with variance equal to v_{ik} .

1 ***Random-effects network meta-analysis model***

2 In the second stage, following the contrast-based parameterisation described by Dias et al.
3 (24) (Example 7(a) in the Appendix, there), in a multi-arm trial, within-trial log ORs are
4 sampled from the following multivariate normal distribution:

$$5 \quad \mathbf{y}_i \sim N_{a_i-1}(\boldsymbol{\theta}_i, \boldsymbol{\Sigma}_i)$$

6 with $\mathbf{y}_i = (y_{i2}, y_{i3}, \dots, y_{ia_i})'$ and $\boldsymbol{\theta}_i = (\theta_{i2}, \theta_{i3}, \dots, \theta_{ia_i})'$ referring to all pairwise comparisons
7 with the baseline arm of trial i and

$$8 \quad \boldsymbol{\Sigma}_i = \begin{pmatrix} v_{i2} & cov(y_{i2}, y_{i3}) & \cdots & cov(y_{i2}, y_{ia_i}) \\ cov(y_{i3}, y_{i2}) & v_{i3} & \cdots & cov(y_{i3}, y_{ia_i}) \\ \vdots & \vdots & \ddots & \vdots \\ cov(y_{ia_i}, y_{i2}) & cov(y_{ia_i}, y_{i3}) & \cdots & v_{ia_i} \end{pmatrix}$$

9 being the variance-covariance matrix of trial i with $cov(y_{ij}, y_{il}) = 1/(n_{i1}p_{i1}(1 - p_{i1}))$, $j \neq$
10 $l \in \{2, 3, \dots, a_i\}$ which is the variance of log odds of the baseline arm (obtained using the
11 Delta method). Then, the vector $\boldsymbol{\theta}_i$ of correlated random-effects in trial i is assumed to follow
12 either a multivariate normal distribution (equation (10) in (24)) or conditional univariate
13 normal distributions on θ_{ik} with $k > 2$ given all other arms from 2 to $a_i - 1$ (equation (11) in
14 (24)). Using the consistency equations (Section “One-stage pattern-mixture model”), we can
15 obtain summary log ORs for all possible comparisons in the network.

16 ***Factors that may affect within-trial normality approximation***

17 We used the database of 29 networks from several health-related fields considered in previous
18 work (6). Detailed information on the MOD per network can be found elsewhere (6). For this
19 study, we considered sample size less than 50 participants to represent small trials, and event
20 risk below 5% to be low. Therefore, we characterised a network as ‘susceptible’ to within-
21 trial normality approximation (hereafter ‘susceptible’ network) when there was at least one
22 trial with sample size less than 50 participants and/ or at least one trial-arm with observed
23 event risk less than 5%; otherwise, the network was characterised as ‘non-susceptible’ to
24 within-trial normality approximation (hereafter ‘non-susceptible’ network). We acknowledge
25 that these two categorisations of the networks may not be universally accepted.

26 ***Extent and balance of MOD per trial and network***

1 We used the ‘five-and-twenty rule’ by Sacket et al. (25), which classifies MOD in a trial as
2 resulting in little, intermediate and serious attrition bias, alongside our definition of
3 unbalanced MOD (6) to indicate the trial and networks as having :

- 4 • low MOD (i.e. a trial with a percentage of MOD less than 5%; a network with a *median*
5 percentage of MOD less than 5%);
- 6 • moderate and balanced MOD: moderate MOD (i.e. a trial with a percentage of MOD
7 between 5% and 20%; a network with a *median* percentage of MOD between 5% and
8 20%) which are balanced in the compared arms (i.e. a trial with a difference in the
9 percentage of MOD in the compared arms up to 6.5%; a network with a *median*
10 difference in the percentage of MOD in the compared arms up to 6.5%);
- 11 • moderate and unbalanced MOD: moderate MOD which are unbalanced in the compared
12 arms (i.e. a trial with a difference in the percentage of MOD in the compared arms
13 above 6.5%; a network with a *median* difference in the percentage of MOD in the
14 compared arms above 6.5%);
- 15 • large and balanced MOD: large MOD (i.e. a trial with a percentage of MOD over 20%;
16 a network with a *median* percentage of MOD over 20%) which are balanced in the
17 compared arms, and,
- 18 • large and unbalanced MOD: large MOD which are unbalanced in the compared arms.

19 Overall, 37% of the 539 trials in our dataset had low MOD, followed by 30% with moderate
20 and balanced MOD, 18% with moderate and unbalanced MOD, 9% with large and
21 unbalanced MOD, and 6% with large and balanced MOD. Almost half of the networks were
22 classified as having moderate and balanced MOD (Table 1), followed by low MOD (41%).
23 Overall, three networks were found to be more problematic in terms of MOD: two networks
24 of moderate and unbalanced MOD, and one network of large and unbalanced MOD. None of
25 the networks was classified as having large and balanced MOD.

26 ***Characteristics of the analysed networks***

27 Eleven out of 29 networks (38%) were categorised as ‘susceptible’ and 18 as ‘non-
28 susceptible’ (Table 1; Supplementary Table 1, Additional file 1). The former included
29 considerably more trials (median: 21, range: 11 – 104) and therefore, more trials per
30 comparison (median: 2, range: 1 – 13) than the latter category (median: 9, range: 4 – 15 for
31 trials; median: 1, range: 1 – 10 for trials per comparison) (Table 1). Of the 11 ‘susceptible’
32 networks, the majority (72%) had trials with moderate and balanced MOD, whereas the

1 majority (55%) of ‘non-susceptible’ networks had trials with low MOD (Table 1). There were
2 four networks with the most severe cases of MOD overall: one ‘susceptible’ network with
3 moderate and unbalanced MOD, two ‘non-susceptible’ networks with moderate and
4 unbalanced MOD, and one ‘non-susceptible’ network with large and unbalanced MOD. The
5 sample size of the trials was moderate overall (median: 204 and 364 in ‘susceptible’ and ‘non-
6 susceptible’ networks, respectively; Table 1); however, nine of the ‘susceptible’ networks
7 included at least one trial with less than 50 participants (Supplementary Table 1, Additional
8 file 1). Median event risk indicated frequent events in both network categories (median: 0.58
9 and 0.66 in ‘susceptible’ and ‘non-susceptible’ networks, respectively; Table 1). Four of the
10 ‘susceptible’ networks included at least one trial with event risk less than 5% (Supplementary
11 Table 1, Additional file 1). Nine ‘susceptible’ networks had at least one trial with zero events
12 or non-events (median number of zero cells: 1, range: 1 – 4; Table 1; Supplementary Table 1,
13 Additional file 1).

14 [Table 1]

15 ***Model implementation and presentation of results***

16 Both approaches were implemented in JAGS via the R-package R2jags (26) (statistical
17 software R, version 3.6.1 (27)). Technical details on the specification of the models (i.e. prior
18 distributions, convergence inspection, number of chains and iterations) can be found in
19 Additional file 1. We created scatterplots to illustrate the agreement between results from the
20 one-stage versus two-stage PM approaches for the following three model parameters: a)
21 posterior mean of within-trial log ORs, b) posterior mean of NMA log ORs for comparisons
22 with the reference intervention in each network, and c) the posterior median of τ^2 . We
23 compared the approaches also in terms of the posterior standard deviation of the parameters
24 mentioned above. An agreement was inferred when the points were aligned with the diagonal
25 line. To quantify the agreement, we used the concordance correlation coefficient (CCC) (28)
26 via the R-package epiR (29). The R-package ggplot2 was used to draw the scatterplots (30).

27 **Results of the empirical study**

28 The first panel of Figure 1 shows the posterior mean and standard deviation of the within-trial
29 log ORs across the 11 ‘susceptible’ networks (404 points, Figure 1 A)) and 18 ‘non-
30 susceptible’ networks (172 points, Figure 1 B)) for different amount of MOD. The second
31 panel of Figure 1 presents the posterior mean and standard deviation of the log ORs for the

1 basic parameters of each ‘susceptible’ (104 points, Figure 1 A)) and ‘non-susceptible’
2 network (80 points, Figure 1 B)), and the third panel illustrates the posterior median and
3 standard deviation of τ^2 in the ‘susceptible’ networks (11 points, Figure 1 A)) and ‘non-
4 susceptible’ networks (18 points, Figure 1 B)) for different amount of MOD.

5 *Posterior mean or median*

6 For the ‘susceptible’ networks, one-stage and two-stage PM approaches overall agreed with
7 respect to the posterior mean of within-trial log ORs (CCC: 0.99) and the posterior mean of
8 NMA log ORs (CCC: 0.99) across the different scenarios of MOD (Figure 1 A), first and
9 second panel). An agreement could be also inferred for the posterior median of τ^2 (CCC:
10 0.90), except for four networks with moderate and balanced MOD whose τ^2 estimates were
11 found to be higher under the one-stage PM approach (Figure 1 A), third panel). In more detail,
12 from the left to the right of the plot, the posterior median of τ^2 under the two-stage PM
13 approach was 0.14, 0.26, 0.37, and 0.71 versus 0.20, 0.40, 0.66, and 0.93 under the one-stage
14 PM approach, respectively. These τ^2 estimates corresponded to moderate statistical
15 heterogeneity (network 14; the posterior median of τ^2 was lower than the third quartile of the
16 corresponding predictive distribution for τ^2) and large statistical heterogeneity (networks 11,
17 22, and 27; the posterior median of τ^2 was larger than the third quartile of the corresponding
18 predictive distributions for τ^2). Note that the remaining ‘susceptible’ networks had low
19 statistical heterogeneity as the posterior median of τ^2 was lower than the median of the
20 corresponding predictive distributions for τ^2 . Therefore, in ‘susceptible’ networks with large
21 statistical heterogeneity, the compared approaches did not agree in the estimation of τ^2 as the
22 estimated τ^2 tended to be larger under the one-stage PM approach when compared with the
23 two-stage PM approach.

24 Contrariwise, in ‘non-susceptible’ networks, the compared approaches perfectly agreed
25 with respect to the posterior mean of within-trial log ORs and the posterior mean of NMA log
26 ORs across the different scenarios of MOD (Figure 1 B), second panel). The agreement was
27 almost perfect for the posterior median of τ^2 (CCC: 0.97) apart from one network with
28 moderate and balanced MOD that showed a slightly larger posterior median of τ^2 under the
29 one-stage PM approach (Figure 1 B), third panel). Specifically, the τ^2 estimates were 0.19
30 and 0.27 under the two-stage PM approach and one-stage PM approach, respectively – both
31 estimates indicated moderate statistical heterogeneity for being lower than the third quartile of
32 the selected predictive distribution for τ^2 .

1 ***Posterior standard deviation***

2 In ‘susceptible’ networks, the posterior standard deviation of NMA log ORs was
3 systematically larger under the one-stage PM approach, especially in networks with moderate
4 and balanced MOD (Figure 1 A), second panel). This was expected as the one-stage PM
5 approach accounted for the uncertainty in the estimation of all parameters in the pattern-
6 mixture model (equation (1)), and hence, the uncertainty increased when the available
7 information was limited, namely, the included trials were small with low events and
8 substantial MOD. Contrariwise, in ‘non-susceptible’ networks, the agreement was almost
9 perfect with respect to the posterior standard deviation of NMA log ORs (Figure 1 B), second
10 panel).

11 Regarding the posterior standard deviation of τ^2 , the agreement was higher in ‘non-
12 susceptible’ networks overall (CCC: 0.96, 95% confidence interval (CI): 0.91 to 0.99) as
13 compared with the ‘susceptible’ networks (CCC: 0.91, 95% CI: 0.82 to 0.95). In the
14 ‘susceptible’ networks, the one-stage PM approach resulted in larger posterior standard
15 deviation of τ^2 for the aforementioned four networks (Section ‘Posterior mean or median’)
16 (Figure 1 A) and B), third panel). Therefore, in ‘susceptible’ networks with large statistical
17 heterogeneity, the one-stage PM approach tended to estimate τ^2 also with larger uncertainty
18 as compared to the two-stage PM approach.

19 **Simulation study**

20 We simulated 1000 triangle networks of two-arm trials and three interventions: new
21 intervention, old intervention, and placebo. Our main interest was the comparison of the
22 former two interventions; however, for completeness we also presented the results on the
23 basic parameters (i.e. comparisons with placebo).

24 ***Simulation set-up***

25 The simulation set-up was in line with a previous study on MOD in NMA (5). Briefly, we
26 assumed a larger *beneficial* underlying log OR for ‘new intervention versus placebo’ as
27 compared to ‘old intervention versus placebo’ and we used the consistency equation to obtain
28 the underlying log OR for ‘new versus old intervention’ (Table 2). To generate the number of
29 events in each arm of every trial, we considered the data-generating model of Hartung and
30 Knapp for a random-effects pairwise meta-analysis (31). For a brief description of the data-
31 generating model, the reader can refer to Additional file 1. To obtain the event risks among

1 the completers in each arm of every trial, we used the linkage function of Turner et al. (4)
2 (equation 7, there) that is a function of the IMOR parameter, the underlying event risks and
3 the probability of MOD in each arm of every trial.

4 ***Simulation scenarios***

5 In the present work, we considered only a ‘typical loop’ with one trial comparing ‘new versus
6 old intervention’, three trials comparing a ‘new intervention with placebo’, and four trials
7 comparing an ‘old intervention with placebo’ (32) (Table 2). The simulation scenarios were
8 constructed such that to explore the impact of four key factors: the sample size of the trials,
9 frequency of events, the extent of MOD, and degree of τ^2 . With respect to sample size, we
10 considered a trial as having a small sample size if $n < 50$, and moderate sample size if $n >$
11 100 , equally distributed in the compared arms (Table 2). For event risk at the control arm, a
12 maximum of 15% was considered to be low, and at least 27% was considered to be frequent
13 (Table 2). Initially, we considered a maximum of 5% as low event risk at the control arm.
14 However, this scenario resulted in generating networks with zero events in both arms for the
15 majority of trials, particularly for the scenario of fewer than 50 participants, and thus, creating
16 serious convergence issues in both approaches. We focused on scenarios of unbalanced MOD
17 with more MOD in the control arm and cases of moderate and large MOD (Table 2). A
18 previous study revealed that moderate and large MOD (which were unbalanced in the
19 compared arms) affected the performance of the one-stage PM approach in terms of the
20 posterior standard deviation of log OR and τ^2 (5). We considered informative missingness
21 process in all interventions: IMOR equal to 2 for the new and old interventions (i.e. the odds
22 of an event among MOD is be twice the odds of an event among completers) and IMOR equal
23 to 1/2 for placebo. We considered τ^2 equal to 0.02 and 0.07 to reflect small and substantial
24 true statistical heterogeneity, respectively. These values correspond to the median of the
25 predictive log-normal distribution for all-cause mortality (95% prior interval: 0.001 – 0.26)
26 and generic health setting (95% prior interval: 0.002 – 2.67), respectively (33). Table 2
27 illustrates the scenarios considered in the simulation.

28 [Table 2]

29 ***Model implementation and presentation of results***

30 For each of the 16 scenarios (4 factors of two categories), we performed a Bayesian random-
31 effects NMA with consistency equations using the one-stage and two-stage PM approaches to

1 analyse the generated networks. All analyses were performed under the ‘on average MAR’
2 assumption as the recommended primary analysis (9,34,35). We assigned a predictive prior
3 distribution on τ^2 that refers to the improvement of symptoms for pharmacological versus
4 placebo comparison (median: 0.11, 95% prior interval: 0.01 – 2.13) and aligns with the
5 beneficial outcome considered in the simulation study (33). We preferred this prior
6 distribution to a weakly-informative prior distribution, such as half-normal prior distribution
7 on τ with variance one (median: 0.67, 95% prior interval: 0.03 – 2.24), as the latter
8 compromised the estimation of the parameters for the scenario of low events (Supplementary
9 Table 2–5, Additional file 1).

10 For each scenario, we calculated the bias for (NMA) log OR as the difference between the
11 posterior mean of log OR and the underlying log OR. The bias for τ^2 was calculated as the
12 difference between the posterior median of τ^2 and the underlying τ^2 . The posterior width of
13 95% credible interval (CrI) for a parameter (log OR or τ^2) was calculated as the difference
14 between the 97.5% and 2.5% percentile of the simulated parameter. The bias of the posterior
15 mean and the width of the 95% CrIs of log OR for every comparison are illustrated using dot
16 plots. The posterior mean and standard deviation of log ORs are presented in tables in the
17 Additional file 1 (Supplementary Table 6 – 8). The posterior median and standard deviation of
18 τ^2 alongside the bias and the width of the 95% CrI are presented in Table 3. Note that
19 regarding the bias and the width of the 95% CrIs of log OR, we presented only the results for
20 small τ^2 as the behaviour of the compared approaches was similar under small and substantial
21 true τ^2 .

22 To demonstrate that there is an association between the within-trial log OR and its standard
23 error when normality approximation cannot be defended (i.e. small trials with low events), we
24 used the simulated triangles to estimate the covariance between the within-trial log OR and its
25 standard error at the first stage of the two-stage PM approach. We created a scatterplot for
26 each scenario where we plotted the estimated within-trial standard error of log OR against the
27 within-trial log OR, and we used different colours to illustrate the magnitude of covariance.
28 We presented the results for ‘new versus old intervention’ in the main text and the results for
29 the comparisons with placebo as Supplementary Figures 1 – 2 (Additional file 1).

30 For each simulation, we used three parallel chains with different initial values; thinning
31 equal to 10; 80,000 updates; and a burn-in of 20,000 Monte Carlo Markov Chain samples.
32 Simulations and analyses were performed in R (27). The dot plots and scatterplots were
33 created using the R-package ggplot2 (30). The code and necessary material to generate and

1 analyse the triangles are available online in the NEMO_Project repository on GitHub,
2 https://github.com/LoukiaSpin/NEMO_Project.git under the folder ‘Binary outcomes’.

3 **Results of the simulation study**

4 *Bias and width of 95% credible interval of log ORs*

5 For the case of low event and small trial size, we encountered small-scale convergence issues
6 for the log OR of all comparisons under the one-stage PM approach alone (1% to 4% of
7 simulations whose results were discarded). In both approaches, the absolute bias of the
8 posterior mean of log OR for ‘new versus old intervention’ was smaller under all scenarios as
9 compared to the bias of posterior mean of log OR for both basic parameters (Figure 2). The
10 one-stage PM approach overestimated the posterior mean of log OR for ‘new versus old
11 intervention’ in the presence of small trials with low event frequency, and notably, for large
12 MOD (Figure 2). On the contrary, the bias in the two-stage PM approach was very low for
13 those scenarios (bias equal to 0.03). In the remaining scenarios, the bias of the posterior mean
14 of log OR for ‘new versus old intervention’ was similar in both approaches.

15 Interestingly, the posterior mean of the log OR for both basic parameters was substantially
16 underestimated in both approaches in the presence of large MOD (Figure 2). For low event
17 and small trial size, both basic parameters had smaller bias under the one-stage PM approach
18 – except for large MOD, where the log OR for ‘old intervention versus placebo’ was slightly
19 more biased under the one-stage approach (Figure 2; Supplementary Table 7–8, Additional
20 file 1). In the remaining scenarios, the bias of the posterior mean of log OR for the basic
21 parameters was similar in both models (Figure 2; Supplementary Table 7–8, Additional
22 file 1).

23 The relatively high negative bias in the basic parameters under both approaches may be
24 attributed to the residual bias after considering the MAR assumption to analyse informative
25 MOD, which were assumed to be moderate or large in all included trials. To investigate
26 whether the extent of MOD may indeed explain this extent of bias, we re-run the simulation
27 study considering also low attrition bias ($\%MOD < 5$) in all included trials. Under this best-
28 case situation, the bias in log OR of the basic parameters was reduced in both approaches.
29 Specifically, the bias ranged from -0.1 (moderate trial size with frequent events and
30 substantial τ^2) to 0.07 (small trials with low event and small τ^2) under the one-stage PM
31 approach, and from -0.19 (small trials with low event and substantial τ^2) to -0.05 (frequent
32 events and small τ^2) under the two-stage PM approach (Supplementary Figure 3, Additional

1 file 1). Therefore, increasing the amount of MOD increased the bias in both basic parameters,
2 particularly under the two-stage PM approach. Note that in each network of our database, the
3 percentage of MOD (%MOD) was ranging from very low levels (indicating low attrition bias;
4 %MOD < 5) to moderate or large levels (indicating serious attrition bias; %MOD > 20) across
5 the trials. Thus, we consider our simulation study to reflect a rather worst-case situation, and
6 that in a ‘typical’ NMA, the bias in the log OR of the basic parameters would be at lower
7 levels.

8 The 95% CrIs of log OR were wider in the one-stage PM approach for all comparisons –
9 especially, for small trials with low events, and large MOD (range: 5.79 – 6.85 under the one-
10 stage PM approach; range: 3.53 – 4.45 under the two-stage PM approach) (Figure 3). Under
11 these scenarios, the available information was limited and therefore, both approaches
12 estimated log OR with greater uncertainty as compared to scenarios with more information
13 (e.g., moderate trial size and/ or frequent events). However, since the one-stage PM approach
14 inherently treats all parameters of the pattern-mixture model (equation (1)) as random
15 variables, was the uncertainty around the estimation of log OR larger under this approach in
16 ‘susceptible’ networks with considerable MOD. Contrariwise, the two-stage PM approach
17 estimated the within-trial log ORs and their standard error at the first stage (via the pattern-
18 mixture model), and hence, ‘disregarded’ the uncertainty in their estimation at the second
19 stage leading to spuriously more precise summary log ORs even in the presence of large
20 MOD.

21 *Ad hoc analysis: Association between the within-trial log OR and its standard error*

22 Figure 4 illustrates a panel of scatterplots on the within-trial standard error of log OR for ‘new
23 versus old intervention’ (y) against the within-trial log OR for that comparison (x) for each
24 simulation scenario. For positive values of x , the covariance between x and y was positive,
25 and therefore, trials with larger positive x corresponded to larger y and received smaller
26 weight, whereas trials with smaller positive x corresponded to smaller y and received larger
27 weight. On the contrary, for negative values of x , the covariance between x and y was
28 negative, and therefore, bias was upwarded for the pooled log OR. This pattern was observed
29 for trials with small size and/ or low event frequency, regardless of τ^2 , and became more
30 evident for large MOD (Figure 4). The conclusions were the same for the comparison of new
31 and old intervention versus placebo (Supplementary Figure 2–3, Additional file 1).

32 *Bias and width of 95% credible interval of common τ^2*

1 Both approaches achieved convergence in all scenarios regarding τ^2 . Under small true τ^2 ,
2 both approaches estimated a similarly low posterior median of τ^2 for moderate trial size and
3 frequent events that approached the truth regardless of the MOD scenario (Table 3). In the
4 remaining scenarios, both approaches overestimated τ^2 similarly for moderate and large
5 MOD, though the bias was slightly larger under the one-stage PM approach (from 0.05 to
6 0.11) as compared to the two-stage PM approach (from 0.05 to 0.08), especially, for small
7 trials with low event. The overestimation may be attributed to having a small true τ^2 which
8 has the same likelihood with the first quartile of the prior predictive distribution that we
9 assigned on τ^2 in both approaches (equal to 0.02), and thus, τ^2 was overestimated.

10 The conclusions were similar for substantial true τ^2 (Table 3). As expected, the posterior
11 median of τ^2 was slightly larger in both approaches in most scenarios compared to the
12 posterior median of τ^2 under small true τ^2 . However, bias was lower under substantial true τ^2
13 in all scenarios as compared to small true τ^2 . A plausible explanation may be that the
14 substantial true τ^2 was much closer to the median of the prior predictive distribution that we
15 assigned on τ^2 in both approaches (equal to 0.11), and hence, the magnitude of
16 overestimation was relatively smaller under substantial true τ^2 than under small true τ^2 .

17 Overall, the one-stage PM approach led to wider 95% CrIs for τ^2 as compared to the two-
18 stage PM approach, especially, for small trials with low events (Table 3). As expected, in both
19 approaches, 95% CrIs for τ^2 were wider under substantial τ^2 (range: 0.57 – 3.29 in the one-
20 stage PM approach; 0.56 – 1.21 in the two-stage PM approach) when compared with small τ^2
21 (range: 0.31 – 3.06 in the one-stage PM approach; 0.31 – 1.19 in the two-stage PM approach)
22 as well as under large MOD (range: 0.40 – 3.29 in the one-stage PM approach 0.42 – 1.21 in
23 the two-stage PM approach) as compared to moderate MOD (range: 0.31 – 2.58 in the one-
24 stage PM approach; 0.31 – 1.15 in the two-stage PM approach). In the case of moderate trial
25 size with frequent events, both approaches led to very similar width of 95% CrI for τ^2
26 regardless of the MOD scenario.

27 [Table 3]

28 Discussion

29 We compared the one-stage approach with the two-stage approach in the presence of MOD
30 via the pattern-mixture model using Bayesian random-effects NMA. We performed an
31 empirical and simulation study to investigate the behaviour of NMA log OR and τ^2 under

1 moderate or large MOD and design-factors that implicate the within-trial approximate
2 normality assumption in the two-stage approach (i.e. sample size and event frequency).

3 The empirical study revealed that in the case of ‘susceptible’ networks with moderate
4 MOD the posterior standard deviation of NMA log OR was systematically larger under the
5 one-stage PM approach. The simulation study indicated that this behaviour was more evident
6 in the presence of small trials with low events and exacerbated for large MOD. This is a
7 situation where the available information is limited, and therefore, the uncertainty around the
8 estimated NMA log OR increases. Our results are in line with Stijnen et al. (17) – albeit the
9 authors applied binomial-normal and hypergeometric-normal models in the absence of MOD.

10 Furthermore, the empirical study did not indicate any systematic differences in the
11 posterior mean of within-trial log ORs and NMA log ORs (for the basic parameters) between
12 the compared approaches across the different amount of MOD. Nevertheless, the simulation
13 study revealed that in networks of small trials with low events and large MOD, the one-stage
14 PM approach resulted in relatively higher positive bias of NMA log OR for ‘new versus old
15 intervention’ (functional parameter) as compared to the two-stage PM approach. This
16 behaviour may be an artefact of the consistency equation, which is implicit also for the bias of
17 NMA log OR for ‘new versus old intervention’ (see, Additional file 1). Presenting only the
18 simulation results for the functional parameter(s) of interest may be misleading, if there is
19 substantial bias in at least one of the basic parameters, as the bias on the functional
20 parameter(s) may be cancelled out to a great extent through the consistency equation,
21 especially, in the two-stage PM approach.

22 In the presence of large statistical heterogeneity, the empirical study revealed that the one-
23 stage PM approach tended to provide a larger estimate of τ^2 as compared to the two-stage PM
24 approach for ‘susceptible’ networks. This observation also concurred with moderate and
25 balanced MOD. Both a previous study (5) and the present simulation study did not indicate
26 any implications of the amount of MOD on the estimation of τ^2 ; though, large MOD led to
27 greater uncertainty in the estimation of τ^2 and we observed this behaviour in our simulation
28 study – more notably for the one-stage PM approach (5). However, our simulation study did
29 not reveal the same large discrepancy in the compared approaches concerning the estimation
30 of τ^2 in networks of small trials with low event and substantial true τ^2 . A plausible
31 explanation may be that the substantial true τ^2 was much lower than the estimated τ^2 in the
32 empirical study (minimum equal to 0.20) to be able to capture a larger discrepancy in the
33 compared approaches. Both true values for τ^2 referred to a ‘typical’ meta-analysis with small

1 or substantial statistical heterogeneity. Therefore, we consider the four networks with large
2 estimation of τ^2 under the one-stage PM approach to represent a rather extreme situation.

3 The parameter τ^2 is a nuisance parameter in the random-effects model that has no intuitive
4 clinical interpretation as opposed to log OR. Nevertheless, τ^2 is an important parameter in the
5 context of inconsistency when we evaluate the certainty of the evidence from a pairwise or
6 network meta-analysis using the GRADE framework (36,37). The magnitude of τ^2 affects our
7 decision to downgrade (and by how many levels) or not the evidence for inconsistency: the
8 larger the τ^2 the more likely to downgrade the evidence for the investigated outcome.
9 Therefore, how much accurately τ^2 is estimated in a model is of critical importance. Our
10 simulation study revealed that both approaches had a similar behaviour overall, except for
11 networks of small trials with low event where the one-stage PM approach led to a slightly
12 larger bias in the estimation of τ^2 . Nonetheless, this should not be viewed as a reason to
13 prefer the two-stage PM approach over the one-stage PM approach, because, in such
14 networks, the two-stage PM approach cannot be reliable for relying on the normality
15 approximation.

16 The ignorance of the inherent correlation between the within-trial log OR and within-trial
17 standard error in conjunction with considerable MOD also raises concerns for the credibility
18 of the results from the two-stage PM approach, particularly, in networks of small trials with
19 low event frequency (15,38). As already illustrated in Figure 4, there is positive association
20 between the within-trial log OR and its standard error when the within-trial log ORs are
21 positive, but negative association when the within-trial log ORs are negative and this pattern
22 was obvious in networks of small trials with low event. Stijnen et al. (17) noted that a positive
23 or negative association between within-trial log OR and its standard error will result in
24 downward or upward bias in log OR, respectively. In our study, this implication was obvious
25 only for the basic parameters. As we already mentioned, implying consistency in the bias for
26 the ‘new versus old intervention’ led to smaller (yet positive) bias when compared with the
27 bias for the basic parameters.

28 The flexibility of the one-stage PM approach comes at a high computational cost as it
29 appeared 10-fold more computationally exhaustive compared with the two-stage PM
30 approach. Not surprisingly, convergence issues occurred for the estimation of the NMA log
31 OR in the networks of small trials and low event frequency only under the one-stage PM
32 approach. The use of continuity correction seems to aid the convergence of the two-stage PM
33 approach for the NMA log OR in this particular scenario. Nevertheless, both approaches share
34 a common limitation: the assumption of normally distributed random-effects which, if

1 deemed inappropriate (e.g. there are outlying trials in the synthesised dataset (15)), may
2 compromise the validity of the results (17). Using a simulation study to compare seven
3 models for random-effects meta-analysis in the frequentist framework, Jackson et al. (18)
4 demonstrated that both the binomial-normal (one-stage approach) and normal-normal (two-
5 stage approach) models performed poorly overall. The authors suggested alternative model
6 parameterisations (model 4, 6 and 7, there) especially when the event is low or there is
7 considerable statistical heterogeneity according to visual inspection of the forest plot.
8 Extending these models to incorporate the pattern-mixture model in the Bayesian framework
9 may be proper alternatives to the current one-stage and two-stage PM approaches.

10 **5 Conclusions**

11 The two-stage PM approach is straightforward to implement for having easier
12 parameterisation, no convergence issues, and shorter convergence time as compared to the
13 one-stage PM approach. Nevertheless, the well-known statistical shortcomings of this
14 approach that relate to its approximate normal likelihood assumption and the inability to learn
15 about the missingness mechanisms (since the missingness parameter is fixed rather than
16 estimated) render this approach less appealing overall for the analysis of MOD. The one-stage
17 PM approach tackles these limitations, and thus, it may be considered as a more appropriate
18 approach. However, the simulation study failed to demonstrate the one-stage PM approach as
19 superior due to considerable bias in the NMA log ORs, especially for large MOD, which can
20 be slightly lower or similar to the corresponding bias under the competing approach. Until a
21 more competent model is developed, we advise the researchers to apply the one-stage PM
22 approach to handle MOD, provided that the limitations of this approach (as demystified in the
23 present empirical and simulation study) are fully acknowledged in the discussion of the NMA
24 results.

25 **Abbreviations**

26 CCC: concordance correlation coefficient; CI: confidence interval; CrI: credible interval;
27 IMOR: informative missingness odds ratio; MAR: missing at random; MOD: missing
28 outcome data; NMA: network meta-analysis; OR: odds ratio.

29 **Declarations**

30 **Ethics approval and consent to participate**

1 Not applicable.

2 **Consent to publish**

3 Not applicable.

4 **Availability of data and materials**

5 The datasets generated and/or analysed during the current study are available in the
6 NEMO_Project repository on GitHub, https://github.com/LoukiaSpin/NEMO_Project.git
7 under the folder ‘Binary outcomes’.

8 **Competing interests**

9 The authors declare that they have no competing interests.

10 **Funding**

11 This work was supported by the German Research Foundation (Deutsche
12 Forschungsgemeinschaft under grant number SP 1664/1–1) to LMS. The funder was not
13 involved in the study design; in the collection, analysis and interpretation of data; in the
14 writing of the report; and in the decision to submit the article for publication.

15 **Authors’ Contributions**

16 LMS conceived the idea of the study. All authors designed the study. LMS analysed the
17 empirical data. LMS and CK performed the simulations. CK and KP checked the code for
18 correctness. LMS drafted the article. All authors revised the article critically for important
19 intellectual content and approved the final version of the article.

20 **Acknowledgements**

21 Chrysostomos Kalyvas is employed by Merck Sharp & Dohme. Katerina Papadimitropoulou
22 is a PhD candidate at the Department of Clinical Epidemiology of Leiden University Medical
23 Center. The authors alone are responsible for the views expressed in this article, and they
24 should not be construed with the views, decisions, or policies of the institutions with which
25 they are affiliated to.

26 **References**

- 1 1. Akl EA, Carrasco-Labra A, Brignardello-Petersen R, Neumann I, Johnston BC, Sun X,
2 et al. Reporting, handling and assessing the risk of bias associated with missing
3 participant data in systematic reviews: a methodological survey. *BMJ Open*.
4 2015;5(9):e009368.
- 5 2. Kahale LA, Diab B, Brignardello-Petersen R, Agarwal A, Mustafa RA, Kwong J, et al.
6 Systematic reviews do not adequately report or address missing outcome data in their
7 analyses: a methodological survey. *J Clin Epidemiol*. 2018;99:14–23.
- 8 3. Spineli LM, Pandis N, Salanti G. Reporting and handling missing outcome data in
9 mental health: a systematic review of Cochrane systematic reviews and meta-analyses.
10 *Res Synth Methods*. 2015;6(2):175–87.
- 11 4. Turner NL, Dias S, Ades AE, Welton NJ. A Bayesian framework to account for
12 uncertainty due to missing binary outcome data in pairwise meta-analysis. *Stat Med*.
13 2015;34(12):2062–80.
- 14 5. Spineli LM, Kalyvas C, Pateras K. Participants' outcomes gone missing within a
15 network of interventions: Bayesian modeling strategies. *Stat Med*. 2019;38(20):3861–
16 79.
- 17 6. Spineli LM. An empirical comparison of Bayesian modelling strategies for missing
18 binary outcome data in network meta-analysis. *BMC Med Res Methodol*.
19 2019;19(1):86.
- 20 7. White IR, Higgins JPT, Wood AM. Allowing for uncertainty due to missing data in
21 meta-analysis--Part 1: two-stage methods. *Stat Med*. 2008;27(5):711–27.
- 22 8. Little RJA. Pattern-Mixture Models for Multivariate Incomplete Data. *J Am Stat*
23 *Assoc*. 1993;88(421):125–34.
- 24 9. Higgins JP, White IR, Wood AM. Imputation methods for missing outcome data in
25 meta-analysis of clinical trials. *Clin Trials*. 2008;5(3):225–39.
- 26 10. Chaimani A, Mavridis D, Higgins JPT, Salanti G, White IR. Allowing for informative
27 missingness in aggregate data meta-analysis with continuous or binary outcomes:
28 Extensions to metamiss. *Stata J*. 2018;18(3):716–40.
- 29 11. Bradburn MJ, Deeks JJ, Berlin JA, Localio AR. Much ado about nothing: a comparison

- 1 of the performance of meta-analytical methods with rare events. *Stat Med.*
2 2007;26(1):53–77.
- 3 12. Sweeting MJ, Sutton AJ, Lambert PC. What to add to nothing? Use and avoidance of
4 continuity corrections in meta-analysis of sparse data. *Stat Med.* 2004;23(9):1351–75.
- 5 13. Davey J, Turner RM, Clarke MJ, Higgins JPT. Characteristics of meta-analyses and
6 their component studies in the Cochrane Database of Systematic Reviews: a cross-
7 sectional, descriptive analysis. *BMC Med Res Methodol.* 2011;11:160.
- 8 14. Nikolakopoulou A, Chaimani A, Veroniki AA, Vasiliadis HS, Schmid CH, Salanti G.
9 Characteristics of networks of interventions: a description of a database of 186
10 published networks. *PLoS One.* 2014;9(1):e86754.
- 11 15. Jackson D, White IR. When should meta-analysis avoid making hidden normality
12 assumptions? *Biom J.* 2018;60(6):1040–58.
- 13 16. Hamza TH, van Houwelingen HC, Stijnen T. The binomial distribution of meta-
14 analysis was preferred to model within-study variability. *J Clin Epidemiol.*
15 2008;61(1):41–51.
- 16 17. Stijnen T, Hamza TH, Özdemir P. Random effects meta-analysis of event outcome in
17 the framework of the generalized linear mixed model with applications in sparse data.
18 *Stat Med.* 2010;29(29):3046–67.
- 19 18. Jackson D, Law M, Stijnen T, Viechtbauer W, White IR. A comparison of seven
20 random-effects models for meta-analyses that estimate the summary odds ratio. *Stat*
21 *Med.* 2018;37(7):1059–85.
- 22 19. Seide SE, Jensen K, Kieser M. A comparison of Bayesian and frequentist methods in
23 random-effects network meta-analysis of binary data. *Res Synth Methods.*
24 2020;11(3):363–78.
- 25 20. Higgins JP, Whitehead A. Borrowing strength from external trials in a meta-analysis.
26 1996;15(24):2733–49.
- 27 21. Salanti G. Indirect and mixed-treatment comparison, network, or multiple-treatments
28 meta-analysis: many names, many benefits, many concerns for the next generation
29 evidence synthesis tool. *Res Synth Methods.* 2012;3(2):80–97.

- 1 22. Lu G, Ades AE. Assessing evidence inconsistency in mixed treatment comparisons. *J*
2 *Am Stat Assoc.* 2006;101(474):447–59.
- 3 23. Salanti G, Ades AE, Ioannidis JPA. Graphical methods and numerical summaries for
4 presenting results from multiple-treatment meta-analysis: an overview and tutorial. *J*
5 *Clin Epidemiol.* 2011;64(2):163–71.
- 6 24. Dias S, Sutton AJ, Ades AE, Welton NJ. Evidence synthesis for decision making 2: a
7 generalized linear modeling framework for pairwise and network meta-analysis of
8 randomized controlled trials. *Med Decis Mak.* 2013;33(5):607–17.
- 9 25. Sackett DL, Richardson WS, Rosenberg WM, Haynes RB. Evidence-based medicine:
10 how to practice and teach EBM. New York: Churchill Livingstone; 1997.
- 11 26. Su Y, Yajima M. R2jags: Using R to Run ‘JAGS’. R package version 0.5–7. 2015.
12 <https://cran.r-project.org/package=R2jags>.
- 13 27. R Core Team. R: A Language and Environment for Statistical Computing. Vienna,
14 Austria: R Foundation for Statistical Computing; 2019. <https://www.r-project.org>.
- 15 28. Lin LI. A concordance correlation coefficient to evaluate reproducibility. *Biometrics.*
16 1989;45(1):255–68.
- 17 29. Stevenson M. epiR: Tools for the Analysis of Epidemiological Data. R package version
18 1.0-15. 2020. <https://cran.r-project.org/package=epiR>.
- 19 30. Wickham H. ggplot2: Elegant Graphics for Data Analysis. Springer-Verlag New York;
20 2009.
- 21 31. Hartung J, Knapp G. A refined method for the meta-analysis of controlled clinical trials
22 with binary outcome. *Stat Med.* 2001;20(24):3875–89.
- 23 32. Veroniki AA, Mavridis D, Higgins JPT, Salanti G. Characteristics of a loop of
24 evidence that affect detection and estimation of inconsistency: a simulation study.
25 *BMC Med Res Methodol.* 2014;14:106.
- 26 33. Turner RM, Jackson D, Wei Y, Thompson SG, Higgins JPT. Predictive distributions
27 for between-study heterogeneity and simple methods for their application in Bayesian
28 meta-analysis. *Stat Med.* 2015;34(6):984–98.

- 1 34. White IR, Welton NJ, Wood AM, Ades AE, Higgins JPT. Allowing for uncertainty due
2 to missing data in meta-analysis--Part 2: Hierarchical models. *Stat Med.*
3 2008;27(5):728–45.
- 4 35. White IR, Carpenter J, Horton NJ. Including all individuals is not enough: lessons for
5 intention-to-treat analysis. *Clin Trials.* 2012;9(4):396–407.
- 6 36. Zhang Y, Akl EA, Schünemann HJ. Using systematic reviews in guideline
7 development: the GRADE approach. *Res Synth Methods.* 2018. doi:
8 10.1002/jrsm.1313.
- 9 37. Brignardello-Petersen R, Bonner A, Alexander PE, Siemieniuk RA, Furukawa TA,
10 Rochweg B, et al. Advances in the GRADE approach to rate the certainty in estimates
11 from a network meta-analysis. *J Clin Epidemiol.* 2018;93:36–44.
- 12 38. Chang B-H, Hoaglin DC. Meta-Analysis of Odds Ratios: Current Good Practices. *Med*
13 *Care.* 2017;55(4):328–35.

14

15

16

17

18

19

20

21

22

23

24

25

26

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16

Tables

Table 1. Distribution of several characteristics across networks

Characteristic	Susceptible networks ¹ (n = 11)	Non-susceptible networks ¹ (n = 18)	All networks (n = 29)
Total trials per network, <i>median (minimum, maximum)</i>	21 (11, 104)	9 (4, 15)	13 (4, 104)
Trials per comparison <i>median (minimum, maximum)</i>	2 (1, 13)	1 (1, 10)	1 (1, 13)
<i>Degree of missing outcome data (%)</i>			
Low <i>median (minimum, maximum)</i>	0.03 (0.00, 0.57) [2] ²	0.02 (0.00, 0.24) [10]	0.03 (0.00, 0.57) [12]
Moderate and balanced <i>median (minimum, maximum)</i>	0.12 (0.00, 0.62) [8]	0.09 (0.00, 0.37) [6]	0.11 (0.00, 0.62) [14]
Moderate and unbalanced <i>median (minimum, maximum)</i>	0.18 (0.00, 0.45) [1]	0.09 (0.03, 0.27) [1]	0.15 (0.00, 0.45) [2]
Large and unbalanced <i>median (minimum, maximum)</i>	-	0.30 (0.03, 0.87) [1]	0.30 (0.03, 0.87) [1]
<i>Factors that affect within-trial normal approximation</i>			
Trial sample size <i>median (minimum, maximum)</i>	204 (12, 18201)	364 (74, 8240)	262 (12, 18201)
Event risk <i>median (minimum, maximum)</i>	0.58 (0.00, 1.00)	0.66 (0.12, 0.99)	0.60 (0.00, 1.00)
Number of zero-cells <i>median (minimum, maximum)</i>	1 (1, 4) [9]	-	1 (1, 4) [9]

¹A network was ‘susceptible’ to within-trial normality approximation when there was at least one trial with sample size less than 50 participants and/ or at least one trial-arm with observed event risk less than 5%.

²Brackets indicate the number of networks with the studied characteristic.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16

Table 2. Scenarios for the simulation set-up

<i>Number of trials per comparison</i>	
typical loop	$NO = 1, NP = 3, OP = 4$
<i>Trial size ($n_{i,k}^E = n_{i,k}^C = n_i$ in trial i)</i>	
< 50 (small)	$n_i \sim U(12, 39)$ placebo-controlled trials $n_i \sim U(15, 49)$ old-controlled trials
> 100 (moderate)	$n_i \sim U(102, 187)$ placebo-controlled trials $n_i \sim U(128, 241)$ old-controlled trials
<i>Initial event rates of the control arm in trial i</i>	
low events	$p_{i,P}^{C,0} \sim U(0.05, 0.09)$ placebo-controlled trials $p_{i,O}^{C,0} \sim U(0.10, 0.15)$ old-controlled trials
	frequent events
<i>Unbalanced risk of missing outcome data ($q_{i,k}^E < q_{i,k}^C$ in trial i)</i>	
moderate	$q_{i,k}^E \sim U(0.05, 0.10), q_{i,k}^C \sim U(0.11, 0.20)$
large	$q_{i,k}^E \sim U(0.21, 0.30), q_{i,k}^C \sim U(0.31, 0.40)$
<i>Missingness mechanisms via log IMOR</i>	
informative	$\varphi_{i,P} \sim TN(\mu = -\log(2), \sigma^2 = 1, a = \log(1))$ $\varphi_{i,k} \sim TN(\mu = \log(2), \sigma^2 = 1, a = \log(1)) \quad k = N, O$
	<i>Treatment effects</i>
basic parameters	$LOR_{NP} = \ln(2), LOR_{OP} = \ln(1.5)$
functional parameter	$LOR_{NO} = LOR_{NP} - LOR_{OP}$ (consistency equation)
<i>Common between-trial variance</i>	
predictive distribution	$\tau^2 \sim LN(-3.95, 1.34^2)$ (small)
	$\tau^2 \sim LN(-2.56, 1.74^2)$ (substantial)

Note: C, control; E, experimental arm; IMOR, informative missingness odds ratio; LN, log-normal distribution; LOR, log odds ratio; N, new intervention; O, old intervention; P, placebo; T, truncated normal distribution; U, uniform distribution.

Typical loop as defined by Veroniki et al. (32)

Using predictive log-normal distributions that correspond to all-cause mortality and generic health setting for small and substantial between-trial variance, respectively (33).

1

2

3 **Table 3.** Posterior median (and 95% CrI) and bias (and width of 95% CrI) for common τ^2

small τ^2		moderate MOD		large MOD	
trial size	frequency	one-stage	two-stage	one-stage	two-stage
small	low	0.13 (6×10^{-3} , 2.59)	0.10 (6×10^{-3} , 1.14)	0.13 (6×10^{-3} , 3.06)	0.10 (6×10^{-3} , 1.20)
		0.11 (2.58)	0.08 (1.13)	0.11 (3.06)	0.08 (1.19)
moderate	low	0.07 (4×10^{-3} , 0.70)	0.07 (5×10^{-3} , 0.64)	0.08 (5×10^{-3} , 0.97)	0.08 (5×10^{-3} , 0.82)
		0.05 (0.70)	0.05 (0.63)	0.07 (0.96)	0.06 (0.81)
small	frequent	0.09 (5×10^{-3} , 0.94)	0.08 (5×10^{-3} , 0.83)	0.09 (5×10^{-3} , 1.04)	0.09 (6×10^{-3} , 0.91)
		0.07 (0.93)	0.06 (0.82)	0.07 (1.03)	0.06 (0.90)
moderate	frequent	0.04 (3×10^{-3} , 0.31)	0.04 (4×10^{-3} , 0.32)	0.05 (4×10^{-3} , 0.40)	0.05 (4×10^{-3} , 0.42)
		0.02 (0.31)	0.02 (0.31)	0.03 (0.40)	0.03 (0.42)

substantial τ^2		moderate MOD		large MOD	
trial size	frequency	one-stage	two-stage	one-stage	two-stage
small	low	0.13 (6×10^{-3} , 2.52)	0.10 (6×10^{-3} , 1.16)	0.14 (6×10^{-3} , 3.29)	0.10 (6×10^{-3} , 1.21)
		0.05 (2.51)	0.02 (1.15)	0.06 (3.29)	0.02 (1.21)
moderate	low	0.09 (5×10^{-3} , 1.05)	0.08 (5×10^{-3} , 0.86)	0.09 (5×10^{-3} , 1.17)	0.08 (5×10^{-3} , 0.90)
		0.01 (1.05)	0.004 (0.85)	0.02 (1.17)	0.01 (0.89)
small	frequent	0.10 (5×10^{-3} , 1.15)	0.09 (6×10^{-3} , 0.95)	0.10 (5×10^{-3} , 1.26)	0.09 (6×10^{-3} , 1.01)
		0.02 (1.14)	0.01 (0.95)	0.02 (1.25)	0.01 (1.01)
moderate	frequent	0.06 (4×10^{-3} , 0.57)	0.05 (4×10^{-3} , 0.56)	0.06 (4×10^{-3} , 0.58)	0.06 (4×10^{-3} , 0.56)
		-0.02 (0.57)	-0.02 (0.56)	-0.02 (0.57)	-0.02 (0.56)

4 MOD, missing outcome data.

5 Posterior median and 95% CrI are provided in the greyed area, followed by bias and width of 95% CrI (in parenthesis) in

6 the white area.

Figure legends

Figure 1. Scatterplots of the two-stage approach against the one-stage approach with regards to within-trial log OR (first row), NMA log OR (second row), and common τ^2 (third row) in ‘susceptible’ networks (panel A)) and ‘non-susceptible’ networks (panel B)). Different colours indicate the degree and balance of missing outcome data across 29 networks. Results on concordance correlation coefficient (CCC) (mean and 95% confidence interval) appear above each scatterplot. References are found in the Additional file 1. NMA, network meta-analysis; log OR, odds ratio in the logarithmic scale; SD, standard deviation.

Figure 2. Dot plots on the bias of posterior mean of NMA log OR for all pairwise comparisons under one-stage and two-stage approaches while accounting for the degree of missing outcome data (moderate, large) being unbalanced in the compared arms, the size of trials (small, moderate), the event frequency (low, frequent) and small τ^2 . MOD, missing outcome data.

Figure 3. Dot plots on the width of 95% credible interval of NMA log OR for all pairwise comparisons under one-stage and two-stage approaches while accounting for the degree of missing outcome data (moderate, large) being unbalanced in the compared arms, the size of trials (small, moderate), the event frequency (low, frequent) and small τ^2 . MOD, missing outcome data.

Figure 4. A panel of scatterplots on the within-trial standard error of log OR for ‘new versus old intervention’ (axis y) against the within-trial log OR for that comparison (axis x) for each simulation scenario. The colour key indicates the magnitude of covariance between the within-trial standard error of log OR and within-trial log OR for that comparison. MOD, missing outcome data; OR, odds ratio.

Supplementary files

Additional file 1: Supplementary methods, tables and figures (DOCX 1.70 MB)